Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalization, and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That’s the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020. The DAPA-CKD trial tested the hypothesis that […]